These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders. Whitehouse PJ, Kellar KJ. J Neural Transm Suppl; 1987; 24():175-82. PubMed ID: 2960781 [Abstract] [Full Text] [Related]
26. Cholinergic nicotinic receptor involvement in movement disorders associated with Lewy body diseases. An autoradiography study using [(125)I]alpha-conotoxinMII in the striatum and thalamus. Bohr IJ, Ray MA, McIntosh JM, Chalon S, Guilloteau D, McKeith IG, Perry RH, Clementi F, Perry EK, Court JA, Piggott MA. Exp Neurol; 2005 Feb; 191(2):292-300. PubMed ID: 15649484 [Abstract] [Full Text] [Related]
30. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology. Okada H, Ouchi Y, Ogawa M, Futatsubashi M, Saito Y, Yoshikawa E, Terada T, Oboshi Y, Tsukada H, Ueki T, Watanabe M, Yamashita T, Magata Y. Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517 [Abstract] [Full Text] [Related]
31. Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease. Sabbagh MN, Reid RT, Corey-Bloom J, Rao TS, Hansen LA, Alford M, Masliah E, Adem A, Lloyd GK, Thal LJ. J Neural Transm (Vienna); 1998 Oct; 105(6-7):709-17. PubMed ID: 9826113 [Abstract] [Full Text] [Related]
32. Cholinergic receptor binding and autoradiography in brains of non-neurological and senile dementia of Alzheimer-type patients. Lang W, Henke H. Brain Res; 1983 May 16; 267(2):271-80. PubMed ID: 6871676 [Abstract] [Full Text] [Related]
33. Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease. Joyce JN, Murray AM, Hurtig HI, Gottlieb GL, Trojanowski JQ. Neuropsychopharmacology; 1998 Dec 16; 19(6):472-80. PubMed ID: 9803423 [Abstract] [Full Text] [Related]
34. Prostate stem cell antigen interacts with nicotinic acetylcholine receptors and is affected in Alzheimer's disease. Jensen MM, Arvaniti M, Mikkelsen JD, Michalski D, Pinborg LH, Härtig W, Thomsen MS. Neurobiol Aging; 2015 Apr 16; 36(4):1629-1638. PubMed ID: 25680266 [Abstract] [Full Text] [Related]
35. High-affinity choline uptake carrier in Alzheimer's disease: implications for the cholinergic hypothesis of dementia. Pascual J, Fontán A, Zarranz JJ, Berciano J, Flórez J, Pazos A. Brain Res; 1991 Jun 21; 552(1):170-4. PubMed ID: 1913175 [Abstract] [Full Text] [Related]
40. Loss of Cholinergic Receptor Muscarinic 1 (CHRM1) Protein in the Hippocampus and Temporal Cortex of a Subset of Individuals with Alzheimer's Disease, Parkinson's Disease, or Frontotemporal Dementia: Implications for Patient Survival. Sabbir MG, Speth RC, Albensi BC. J Alzheimers Dis; 2022 Aug 18; 90(2):727-747. PubMed ID: 36155524 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]